Table 6.
Synopsis of the Crosstalk between miRNA and lncRNA for influencing metastasis
| Cancer | Pre-clinical | Mechanism | miRNA | lncRNA | Therapeutic intervention for tumor regression | Cellular Signaling | Ref. |
|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | in vivo | Down regulation | miR-26a | DLX6-AS1 |
knockdown of DLX6-AS1 inhibited RCC |
PTEN | [156] |
| Brain cancer and glioma | in vivo | Down regulation | miR-107 | DLX6-AS1 | Knockdown of miR-107 inhibited brain cancer | BDNF-dependent | [157] |
| Brain cancer and glioma | in vivo | miR-10b | GAS5 | NA | PIP3K, AKT, ERK and MEK | [158] | |
| Glioma | in vivo | Sponging | miR-18a-5p | GAS5 | overexpression of GAS5 inhibits glioma cells | PTEN–PI3K–AKT– mTOR | [159] |
| Renal cell carcinoma and hepatocellular cell carcinoma | in vivo | Sponging | MiR-34a | GAS5 | NA | p53 | [160] |
| Breast cancer | in vivo | NA | miR-21 | GAS5 | Knockdown of miR-21 inhibited breast cancer. | HER2/neu | [161] |
| Osteosarcoma | in vivo | NA | miR-182 | UCA1 | Knockdown of UCA1 inhibited OS. | PTEN/AKT | [160, 162] |
| Leukemia | in vivo | Sponging | miR-126 | UCA1 | Knockdown of UCA1 inhibited ML cells in vitro. | PI3K/AKT and JAK/STAT | [163] |
| Breast cancer | in vivo | Sponging | miR-204 and miR-1 | MALAT1 | knockdown of MALAT1 inhibited breast cancer | MAPK-ERK | [85, 164] |
| Breast cancer | NA | NA | miR-7 | X-inactive-specific transcript (XIST) | NA | NA | [165] |